Discovery of Isotucaresol derivatives as adjuvants for vaccines testing in a SARS-CoV-2 vaccine model

NIH RePORTER · NIH · N01 · $598,808 · view on reporter.nih.gov ↗

Abstract

The long-term goal of the program is the commercial development of synthetic mimetics of novel saponin adjuvants that can be produces as single chemical entities on a large scale, are chemically more stable than current saponin adjuvants.

Key facts

NIH application ID
10488957
Project number
75N93021C00054-0-9999-1
Recipient
INIMMUNE CORPORATION
Principal Investigator
OMER RASHEED
Activity code
N01
Funding institute
NIH
Fiscal year
2021
Award amount
$598,808
Award type
—
Project period
2021-09-01 → 2023-08-31